Study for blistering autoimmune skin diseases
Part of Immune system & allergy, Skin clinical trials.
This study is for adults with certain autoimmune blistering skin conditions. Researchers want to better understand and test treatments that could improve symptoms and healing for people with these specific diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have one of these diagnoses: pemphigus vulgaris, pemphigus foliaceus, or bullous pemphigoid
- You must be able to understand the study and sign consent (give permission yourself)
- You should not have been diagnosed with a different condition than the three listed
- You should not be a University of Pennsylvania employee or student
- You should not have cognitive impairment that prevents you from participating safely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for moderate-to-severe pemphigus vulgaris, a rare skin blistering condition. One group gets rituximab plus corticosteroids, the other gets corticosteroids plus azathioprine. It aims to find which combination works better to control the disease with fewer side effects.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
This study looks at how immune-related skin diseases like bullous pemphigoid and lupus affect blood clotting. The results could help doctors better understand and manage clotting risks in these patients.
This study collects skin samples and medical information from people with skin conditions caused by their immune system. It helps researchers better understand these diseases and develop new treatments.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
This study tests a new drug called CM313 (an antibody that targets a protein on immune cells) for treating pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if it can reduce blisters and improve quality of life, especially for people who haven't responded well to other treatments.
Hear when a new Pemphigus Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.